LOS ANGELES, Aug 20, 2020 (GLOBE NEWSWIRE) – .Portnoy law firm advises investors of Poseida Therapeutics, Inc. ("Poseida Therapeutics" or "Company") (NASDAQ: PSTX) that the firm has initiated an investigation into possible securities fraud and may file class action on behalf of investors.
Investors are encouraged to contact Attorney Lesley F. Portnoy by phone at 310-692-8883 or email firstname.lastname@example.org to discuss their legal rights, or click here to join the case on www .portnoylaw.com. Portnoy law firm can provide a free case assessment and discuss investors' options for pursuing claims for reimbursement of their losses.
On July 10, 2020, Poseida completed its initial public offering ("IPO") and issued 14 million shares of common stock at a price of $ 16.00 per share. On August 18, 2020, Poseida announced that Poseida's Phase 1 clinical trial evaluating autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer by US Food and Drug Administration (" FDA "). This lockdown was included in the study by the FDA to investigate the death of a patient in late July. Poseida's share price fell $ 3.94 per share, or 30.31%, on the news, closing at $ 9.06 per share on August 18, 2020.
Please visit our website to review more information and submit your transaction information.
Portnoy law firm represents investors in pursuing claims arising from corporate infringements. The company's founding partner has confiscated over $ 5.5 billion for aggrieved investors. Lawyer advertising. Previous results do not guarantee similar results.
Lesley F. Portnoy, Esq.
Approved CA and NY bar